A Randomised Trial Of Standard Anthracycline-Based Chemotherapy With Fluorouracil, Epirubicin And Cyclophosphamide (FEC) Or Epirubicin And CMF (Epi-CMF) Versus FEC Followed By Sequential Docetaxel As Adjuvant Treatment For Women With Early Breast Cancer.

Trial Profile

A Randomised Trial Of Standard Anthracycline-Based Chemotherapy With Fluorouracil, Epirubicin And Cyclophosphamide (FEC) Or Epirubicin And CMF (Epi-CMF) Versus FEC Followed By Sequential Docetaxel As Adjuvant Treatment For Women With Early Breast Cancer.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Docetaxel (Primary) ; Cyclophosphamide; Cyclophosphamide; Epirubicin; Fluorouracil; Methotrexate
  • Indications Early breast cancer
  • Focus Adverse reactions; Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms TACT
  • Most Recent Events

    • 14 Dec 2013 Analysis using parametric cure models presented at the 36th Annual San Antonio Breast Cancer Symposium.
    • 08 Dec 2012 Mature survival analysis presented at the 35th Annual San Antonio Breast Cancer Symposium.
    • 16 Feb 2010 United Kingdom Clinical Research Network (3800) reports accrual to date changed from 42% to 43%.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top